Tech Company Financing Transactions

Elucid Funding Round

On 11/9/2023, Elucid raised $80 million in Series C funding from Elevage Medical Technologies.

Transaction Overview

Company Name
Announced On
11/9/2023
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease.

Company Information

Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
2 Park Plaza
Boston, MA 02116
USA
Email Address
Overview
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core.
Profile
Elucid LinkedIn Company Profile
Social Media
Elucid Company Twitter Account
Company News
Elucid News
Facebook
Elucid on Facebook
YouTube
Elucid on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Blake Richards
  Blake Richards LinkedIn Profile  Blake Richards Twitter Account  Blake Richards News  Blake Richards on Facebook
President
Andrew Buckler
  Andrew Buckler LinkedIn Profile  Andrew Buckler Twitter Account  Andrew Buckler News  Andrew Buckler on Facebook
Vice President
Nasibeh Vatankhah
  Nasibeh Vatankhah LinkedIn Profile  Nasibeh Vatankhah Twitter Account  Nasibeh Vatankhah News  Nasibeh Vatankhah on Facebook
VP - Bus. Development
Jason Bottiglieri
  Jason Bottiglieri LinkedIn Profile  Jason Bottiglieri Twitter Account  Jason Bottiglieri News  Jason Bottiglieri on Facebook
VP - Engineering
Murali Ayyapillai
  Murali Ayyapillai LinkedIn Profile  Murali Ayyapillai Twitter Account  Murali Ayyapillai News  Murali Ayyapillai on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/9/2023: Chptr venture capital transaction
Next: 11/9/2023: March Biosciences venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary